ClinicalTrials.Veeva

Menu
N

National Allergy and Asthma Research LLC | North Charleston, SC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dupilumab
OPN-375
Symbicort®
Rocatinlimab
CDX-0159
Bradanicline
BMX-010
EP262
CNP-201
NOC-110

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 20 total trials

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a...

Active, not recruiting
Moderate-to-Severe Atopic Dermatitis
Atopic Eczema
Other: Topical emollient (moisturizer)
Drug: dupilumab

This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and...

Active, not recruiting
Chronic Inducible Urticaria
Drug: Oral EP262

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling
Chronic Spontaneous Urticaria
Drug: Placebo
Drug: Oral EP262

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalatio...

Enrolling
Refractory or Unexplained Chronic Cough
Drug: NOC-110
Other: Placebo

Trial sponsors

Regeneron Pharmaceuticals logo
A
E
LEO Pharma logo
Amgen logo
AnaptysBio logo
A
B
C
Celldex Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems